Canada Antiviral Drugs Market Size & Outlook, 2022-2030
Canada antiviral drugs market, 2018-2030 (US$M)
Related Markets
Canada antiviral drugs market highlights
- The Canada antiviral drugs market generated a revenue of USD 2,245.5 million in 2022 and is expected to reach USD 2,061.0 million by 2030.
- The Canada market is expected to grow at a CAGR of -1.1% from 2023 to 2030.
- In terms of segment, hiv was the largest revenue generating application in 2022.
- Herpes is the most lucrative application segment registering the fastest growth during the forecast period.
Antiviral drugs market data book summary
| Market revenue in 2022 | USD 2,245.5 million |
| Market revenue in 2030 | USD 2,061.0 million |
| Growth rate | -1.1% (CAGR from 2022 to 2030) |
| Largest segment | Hiv |
| Fastest growing segment | Herpes |
| Historical data | 2018 - 2021 |
| Base year | 2022 |
| Forecast period | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | HIV, Hepatitis, Herpes, Influenza |
| Key market players worldwide | Roche Holding AG, GSK PLC ADR, AbbVie Inc, Merck & Co Inc, Johnson & Johnson, Bristol-Myers Squibb Co, Dr Reddy's Laboratories Ltd ADR, Aurobindo Pharma |
Other key industry trends
- In terms of revenue, Canada accounted for 3.1% of the global antiviral drugs market in 2022.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. antiviral drugs market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 2,061.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antiviral Drugs Market Scope
Antiviral Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Canada antiviral drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antiviral drugs market will help companies and investors design strategic landscapes.
Hiv was the largest segment with a revenue share of 34.32% in 2022. Horizon Databook has segmented the Canada antiviral drugs market based on hiv, hepatitis, herpes, influenza covering the revenue growth of each sub-segment from 2018 to 2030.
Canada is anticipated to witness exponential growth opportunities owing to the high disease burden of viral diseases and increasing awareness of therapeutics among the population. The high burden of viral disease is compelling government bodies to implement certain initiatives to combat viral diseases.
For instance, in July 2022, the Canadian government announced an investment of USD 10 million for the development of public health measures, testing approaches, and new vaccines against COVID-19. Moreover, in February 2023, Gilead Sciences, Inc. announced a demonstration of the impact of antiviral innovation at CROI 2023.
Moreover, recent product approvals and ongoing partnerships between market players & governments to increase therapeutics supply are some of the other factors propelling the market growth. For instance, in September 2022, Takeda Canada, Inc. received Health Canada authorization for LIVTENCITY (maribavir), an antiviral treatment for adults with post-transplant CMV infections.
Reasons to subscribe to Canada antiviral drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Canada antiviral drugs market databook
-
Our clientele includes a mix of antiviral drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada antiviral drugs market , including forecasts for subscribers. This country databook contains high-level insights into Canada antiviral drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Canada antiviral drugs market size, by application, 2018-2030 (US$M)
Canada Antiviral Drugs Market Outlook Share, 2022 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
